Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Postmarket Device Surveillance Reforms Raised At Califf Confirmation Hearing

This article was originally published in The Gray Sheet

Executive Summary

Robert Califf responded to questions about improving postmarket device surveillance during his Nov. 17 confirmation hearing, including from HELP Committee Ranking Member Patty Murray, D-Wash., who raised the issue in relation to tainted duodenscopes that led to the deaths of several people in her state. Califf also addressed questions on lab-developed test oversight and charges that FDA overuses guidance documents.

Advertisement

Related Content

Commissioner Califf: Cardiologist, Clinical Trials Expert Ascends At FDA
Scope Firms, FDA Faulted In 300-Page Senate Report Seeking Device Reforms
Califf Expected To Ace Senate Panel Vote, As He Ups Emphasis On Safety Surveillance
CDRH Guidance Priorities Include Lab-Developed Tests, Adverse Event Reporting, Third-Party 510(k) Review
CMS And FDA Stand Together Behind FDA Oversight Of LDTs At House Hearing
Califf Supports Combo Products Pathway At Confirmation Hearing
Califf Supports Combo Products Pathway At Confirmation Hearing
Duodenoscope-Makers Ordered By FDA To Conduct Sec. 522 Postmarket Surveillance Studies
Bacterial Outbreaks Triggering Tougher FDA Reprocessing Standards
CDRH Sets Performance Goals To Reduce Draft Guidance Ambiguity

Topics

Advertisement
UsernamePublicRestriction

Register

MT034390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel